Biopharmaceutical CMO and CRO Market (By Service: Contract Manufacturing and Contract Research; By Source: Mammalian and Non-Mammalian; By Product Type: Biologics and Biosimilars) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023 - 2032


The global biopharmaceutical CMO and CRO market was valued at USD 34 billion in 2022 and is expected to hit USD 62.93 billion by 2032, growing at a compound annual growth rate (CAGR) of 6.4% from 2023 to 2032.

Biopharmaceutical CMO and CRO Market Size 2023 to 2032

To Access our Exclusive Data Intelligence Tool with 15000+ Database, Visit: Precedence Statistics

Key Takeaways

  • North America led the global market with the highest market share of 34% in 2022.
  • Asia-Pacific is expected to expand at the largest CAGR between 2023 and 2032.
  • By Service, the contract manufacturing segment has held the highest market share of 58% in 2022.
  • By Service, the contract research segment is anticipated to grow at the fastest CAGR from 2023 to 2032.
  • By Source, the mammalian segment had a major market share of 54% in 2022.
  • By Source, the non-mammalian segment is projected to expand at the fastest CAGR over the projected period.
  • By Product Type, the biologics segment generated more than 81.5% of revenue share in 2022.
  • By End-use, the biosimilars segment is estimated to grow at the fastest CAGR over the projected period.

Biopharmaceutical CMO and CRO Market in the U.S. 2023-2032

The U.S. biopharmaceutical CMO and CRO market size was valued at USD 7.10 billion in 2022 and is estimated to reach around USD 13.39 billion by 2032, growing at a CAGR of 6.60% from 2023 to 2032.

U.S. Biopharmaceutical CMO and CRO Market Size 2023 to 2032

Based on the region, the North America accounted 34% market share in 2022, in terms of revenue and is estimated to sustain its dominance during the forecast period. This is attributable to the presence of major key players in the region. Moreover, US dominate the biopharmaceutical industry due to the presence of numerous contract manufacturers and contract research organizations in the region. The various small and medium sized pharma developers are increasingly contracting the manufacturing of pharmaceuticals to the CMOs due to lack of investments. Furthermore, the growing burden of diseases in North America have resulted in the higher consumption of biopharmaceutical products, thereby fueling the growth of the biopharmaceutical CMO and CRO market in the region.

On the other hand, Asia Pacific is estimated to be the most opportunistic market during the forecast period owing to the increasing investments of the government for developing healthcare infrastructure. The presence of large population in the region coupled with growing prevalence of various diseases such as diabetes, cancer, and other chronic diseases is anticipated to offer lucrative growth opportunities to the market players in the region.

Biopharmaceutical CMO and CRO Market Share, By Region, 2020 (%)

Growth Factors

Biopharmaceutical CMO and CRO are the abbreviations for biopharmaceutical contract manufacturing organizations and contract research organizations respectively. The market is primarily driven by the rapid growth of the biopharmaceutical industry across the globe. Biopharmaceutical industry represents around 20% of the global pharmaceutical industry. Moreover, growing demand for the biopharmaceutical products amongst the population is indirectly fueling the growth of the biopharmaceutical CMO and CRO market exponentially. CMO helps the biopharmaceutical industry by developing and manufacturing the pharmaceutical products. On the other hand, a CRO helps in the research & development activities outsourced by the biopharmaceutical industry players. Hence, the growth of the biopharmaceutical CMO and CRO market is solely dependent on the biopharmaceutical industry. Further, rising burden of diseases, growing geriatric population, increasing demand for gene therapies, and technological advancements in the field of biotechnology is significantly fueling the growth of the market across the globe.

The shifting preferences of drug developer towards biologics are pumping huge investments in the biopharmaceutical CMO and CRO industry. Moreover, the contract manufacturers are becoming popular as most of the small and medium biopharmaceutical manufacturers are opting for the CMO services in order to save costs relating to pharmaceutical manufacturing. Therefore, the growing dependence of the drug developers on contract manufacturing organizations is significantly driving the global biopharmaceutical CMO and CRO market.

Biopharmaceutical CMO and CRO Market Scope 

Report Highlights Details
Market Size in 2023 USD 36.01 Billion
Market Size by 2032 USD 62.93 Billion
Growth Rate From 2023 to 2032 CAGR of 6.4%
Base Year 2022
Forecast Period 2023 to 2032
Segments Covered Product, Source, Service
Regional Scope North America, APAC, Europe, Latin America, MEAN, Rest of the World
Companies Mentioned Samsung Biologics, Lonza, BoehringerIngelheim, Patheon, CMC Biologics, TOYOBO Co. Ltd., JRS Pharma, RentschlerBiotechnologie, FUJIFILM Diosynth Biotechnologies, WuXi Biologics, PRA Health Sciences, LabCorp

 

Service Insights

By service, the contract manufacturing segment led the market with revenue share of 58% in 2022. This is attributed to the availability of numerous contract manufacturing organizations that significantly contributes in the development and production of biopharmaceuticals on large scale. Hence, this segment is estimated to remain dominant throughout the forecast period.

On the other hand, the contract research segment is expected to gain traction owing to the increasing investment by the small and big biopharma players to indulge in the research & development activities.

Source Insights

By source, the mammalian segment led the market with revenue share of 54% in 2022. This is attributed to the growing importance of the mammalian cell culture for research and development of various antibodies, vaccines, and proteins in the biopharma industry. Mammalian cell line has been extensively used for the development of viral vaccine and diagnostics in the recent years that generated huge revenue for this segment.

Biopharmaceutical CMO and CRO Market Share, By Source, 2020 (%)

On the other hand, the non-mammalian segment is expected to gain considerable traction owing to its increasing use in the manufacturing of bio-therapeutics such as enzymes, hormones, cytokines, and antibodies.

Product Type Insights

By product type, the biologics segment led the market with revenue share 81.5% in 2022. The use of biologics is considered to be much more effective and safer. The growing interests of the pharma developers in the biologics field and rising investment towards this field has sophistically contributed in the growth of this segment.

Biopharmaceutical CMO and CRO Market Share, By Product, 2020 (%)

On the other hand, the biosimilars is expected to grow at a promising rate as it provides low cost solutions and may be used as an alternative to the biologics. However, the lack of reliability and safety issues associated with this segment may restrict the growth of this segment.

Key Companies & Market Share Insights

The market is moderately fragmented with the presence of several local companies. These market players are striving to gain higher market share by adopting strategies, such as investments, partnerships, and acquisitions & mergers. Companies are also spending on the development of improved services. Moreover, they are also focusing on maintaining competitive pricing.

In May 2019, Samsung Biologics entered into a contract with GI Innovation for development of immunochemotherapy. Under this contract, Samsung Biologics will develop a new drug through a combination of protein drugs and human micro-organisms.

This strategical development will foster the market growth by introducing new drugs and encourage innovation in the field of biopharmaceutical contract manufacturing.

Biopharmaceutical CMO and CRO Market Players

  • Lonza
  • JRS Pharma
  • Samsung Biologics
  • CMC Biologics
  • TOYOBO Co. Ltd.
  • RentschlerBiotechnologie
  • FUJIFILM Diosynth Biotechnologies
  • WuXi Biologics
  • Patheon
  • BoehringerIngelheim
  • PRA Health Sciences
  • LabCorp

Segments Covered in the Report

By Service

  • Contract Manufacturing
    • Process Development
      • Upstream
      • Downstream
    • Fill & Finish Operations
    • Analytical & QC studies
    • Packaging
  • Contract Research
    • Inflammation & Immunology
    • Cardiology
    • Oncology
    • Neuroscience
    • Others

By Source

  • Mammalian
  • Non-Mammalian

By Product

  • Biologics
    • Vaccines
    • Monoclonal antibodies (MABs)
    • Recombinant Proteins
    • Antisense, RNAi, & Molecular Therapy
    • Others
  • Biosimilars

By Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
  • Rest of the World

Frequently Asked Questions

What is the current size of biopharmaceutical CMO and CRO market?
The global biopharmaceutical CMO and CRO market size was valued at USD 34 billion in 2022 and is expected to hit USD 62.93 billion by 2032.
What is the CAGR of biopharmaceutical CMO and CRO market?
The biopharmaceutical CMO and CRO market is expected to grow at a compound annual growth rate (CAGR) of 6.4% from 2023 to 2032.
Who are the major players operating in the market?
The major players operating in the biopharmaceutical CMO and CRO market are Lonza, Samsung Biologics, Patheon, CMC Biologics, TOYOBO Co. Ltd., JRS Pharma, RentschlerBiotechnologie, FUJIFILM Diosynth Biotechnologies, WuXi Biologics, BoehringerIngelheim, PRA Health Sciences, LabCorp.
Which are the driving factors of the biopharmaceutical CMO and CRO market?
The rapidly growing biopharmaceutical industry, and growing government expenditure on building sophisticated healthcare infrastructure are the driving factors of biopharmaceutical CMO and CRO market.
Which product is expected to hold the largest share in the biopharmaceutical CMO and CRO market?
The biologics segment dominated largest revenue share of 81.5% in 2022.
What is the North America biopharmaceutical CMO and CRO market worth?
In 2022, the North America region held the 34% market share in the biopharmaceutical CMO and CRO market.

PROCEED TO BUY :

   USD 4900
   USD 3800
   USD 2100
   USD 2100
   USD 7500

ASK FOR SAMPLE

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client

Get a Sample